EMERGE Study

What we are studying

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group study to find out whether an investigational drug called aducanumab has the potential to be a helpful treatment that slows down the disease progression of early Alzheimer’s Disease (AD). This drug will be compared to placebo. During this study we will evaluate the safety (side effects), and find out more about aducanumab.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 50 - 85

Eligibility Criteria

  • Ability to provide consent
  • Minimum of 6 years of education or work experience
  • Positive amyloid PET scan
  • Good overall health
  • Must have a study partner who has frequent contact with the participant and who is willing to attend study visits.

What is involved

  • Approximately 33 clinic visits as well as telephone checks over 18 months
  • Tests of memory and thinking
  • MRI scans
  • PET/CT scan
  • Electrocardiograms
  • Collection of blood
  • Urine
  • Vital signs-including blood pressure
  • Height
  • Weight
  • Collection of heart and breathing rate and temperature

Compensation

Participants may receive up to $1,600 if all visits are completed over 18 months. Screening 1: $25. Screening 2: $25. Screening MRI: $25. 20 Infusion visits: $50 each. 2 optional lumbar puncture: $100 each. 7 MRI scans: $25 each.

Contact Information

Study Coordinator
Tim Collare
Email
[email protected]
Phone
-6463
Principal Investigator
Kaycee Sink, MD

сывороточный протеин

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.